Liposomes, liquid-crystal systems, lipid nanoparticles and nanoemulsions may solve different stability or delivery problems. Particle size alone cannot describe performance, exposure or safety.
Carrier terminology can make a project sound advanced before the technical objective is defined. Starting with the problem clarifies which structure, exposure and safety evidence is actually necessary.
How should a cosmetic carrier be characterised and tested so that dispersion, protection, release, deposition and penetration are not treated as the same benefit?
Carrier value is problem-specific. Structure, size distribution, loading, release, final-formula behaviour, skin location and safety must be connected before a delivery statement is credible.
Define the problem before selecting the carrier
A carrier may be intended to improve dispersion, protect an unstable material, change release, increase deposition or alter sensory behaviour. These objectives are different and need different controls.
Calling a system nano does not show which problem it solves. Composition, structure, loading, release and behaviour in the complete formula must be characterised.
Delivery, deposition and penetration are not synonyms
More material detected in a skin compartment can reflect surface deposition, follicular localisation, barrier interaction or deeper transport. The method and recovery procedure shape the interpretation.
A stronger study separates these locations and asks whether the observed exposure is necessary for the intended cosmetic function.
Safety and regulation start with design
Particle distribution, aggregation, material identity, impurities, long-term exposure and environmental fate should be considered alongside performance. Final-formula processing may also change the original carrier.
The minimum package includes structural characterisation, stability, loading and release, relevant skin-distribution controls, safety review and current target-market classification before claims are drafted.
How the evidence chain connects
- 01
Carrier structure
Confirm composition, morphology, distribution, loading and physical stability.
- 02
Formula transition
Determine whether processing, surfactants, electrolytes and storage preserve or change the carrier.
- 03
Skin location
Separate surface residence, follicular deposition, barrier interaction and deeper penetration.
Experiments that can move the decision forward
Structural characterisation
Method: Use complementary size, distribution, morphology and loading methods before and after formula incorporation.
Decision endpoint: A defined and stable carrier population.
Release and localisation
Method: Pair release testing with recovery-controlled skin distribution or deposition measurements.
Decision endpoint: Location and availability separated from total recovery.
Exposure-led safety review
Method: Review material identity, impurities, aggregation, exposure route and market classification for the final system.
Decision endpoint: A risk question matched to actual use.
What this article cannot establish
- Particle size alone does not establish carrier identity, penetration, efficacy or safety.
- Final-formula processing may change the carrier described in supplier data.
- Terminology and regulatory requirements must be checked for the exact market and product.
Editorial and use boundary
English-edited from the approved GreenDee Muzi digest. Terminology, safety assessment and regulatory requirements must be checked for the exact material, product and market.